Linked Life Data

20141003

Source:http://linkedlifedata.com/resource/pubmed/id/20141003

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-2-9
pubmed:abstractText
The ViroSeq (Celera Diagnostics) and Trugene (Bayer HealthCare) HIV-1 genotyping systems are widely used today in world clinical practice to detect drug resistance mutations resulting from ineffective treatment for HIV infection. Only the former test has gained acceptance. The present study has compared ViroSeq and Trugene genotyping systems used to identify both mutations of drug resistance and those of polymorphism in the HIV variants circulating in Russia where the unique strain IDU-A prevails. Analysis of 18 samples from HIV-infected patients who received and did not receive specific therapy has demonstrated that the agreement of the results of the tests was 95% (180 of the 190 mutations). At the same time, the results of resistance mutation detection by the ViroSeq and Trugene HIV-1 genotyping systems coincided completely. The fact that the Trugene HIV-1 genotyping system may be used along with the ViroSeq test system in clinical diagnostic laboratories is shown in the paper.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0869-2084
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
46-51
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Comparative analysis of ViroSeq and Trugene HIV-1 genotyping systems in the application to the virus variants in Russia].
pubmed:publicationType
Journal Article, Comparative Study, English Abstract